-
Jan 11, 2025 | 
cellandgene.com | Jackie Mulryne |Eftychia Sideri |Heba Jalil |Antony Hitchcock
With over 450 unique products in clinical development and 50 anticipated approvals by 2030, the evolving regulatory landscape for cell and gene therapies is more critical than ever. Don't miss your chance to gain expert insights! Join the next Cell & Gene Live for an exclusive digital panel discussion exploring forward-looking perspectives on this transformative field. Registration is free—thanks to the support of Thermo Fisher Scientific.
-
Jan 8, 2025 | 
advancingrna.com | AR Welch |Advancing RNA |Kishore Kumar Hotha |Antony Hitchcock
Though the number of CDMOs with mRNA/RNA capabilities is increasing, many of these are better equipped for large-scale, linear mRNA development. Don't miss Advancing RNA Live on January 21st as our panel shares how mRNA and next-gen RNA modality companies need to be evaluating CDMO platforms. Attendance is free thanks to the support of Cytiva.
-
Dec 10, 2024 | 
bioprocessonline.com | Antony Hitchcock |AGH Bioconsulting |Junwei Sun |Lucia Fernandez |Lucia Fernández
Let Us Handle Your Buffer PreparationThermo Fisher Scientific is here to support you with the buffer preparation in your manufacturing workflow. Leaving the non-core activities to us enables you to focus on the patient therapy development. Our capabilities cover off-the-shelf products like WFI, NaOH, NaCl, or EtOH, a library of the most frequently used buffers that are made-to-order, as well as fully customized buffers.
-
Dec 10, 2024 | bioprocessonline.com | Antony Hitchcock |AGH Bioconsulting |Junwei Sun |Lucia Fernandez |Lucia Fernández
Let Us Handle Your Buffer PreparationThermo Fisher Scientific is here to support you with the buffer preparation in your manufacturing workflow. Leaving the non-core activities to us enables you to focus on the patient therapy development. Our capabilities cover off-the-shelf products like WFI, NaOH, NaCl, or EtOH, a library of the most frequently used buffers that are made-to-order, as well as fully customized buffers.
-
Dec 2, 2024 | 
cellandgene.com | Antony Hitchcock |AGH Bioconsulting |R.k. DeLong
Webinar: Leveraging Platform Processes for Developing and Accelerating Novel Gene and Cancer TherapeuticsThe FDA's new draft guidance for the Platform Technology Designation Program helps drug developers leverage platform data to speed approvals and improve patient access. In an upcoming webinar, experts will discuss platform processes, supply chain integration, and share insights on combining AAV gene therapy with cytokine immunotherapy to treat cancer. Click here to learn more.
-
Nov 19, 2024 | 
cellandgene.com | Antony Hitchcock |AGH Bioconsulting
By Antony Hitchcock, principal and owner, AGH Bioconsulting
It goes without saying that the last two years have been challenging for the whole of the biotechnology sector, with widespread layoffs and reduced investment in the sector.
-
Sep 20, 2024 | 
cellandgene.com | Laura Keita |Philip Ross |Antony Hitchcock |AGH Bioconsulting
Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery. Better Audits, Faster Through Transparency And EfficiencyClinical trial audits are evolving.
-
Aug 14, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Antony Hitchcock |AGH Bioconsulting
In the first- of this three-part article series, several mRNA execs share their perspectives on the world of partnering in the RNA therapeutics space, assessing first the current state of CDMO partnerships and how they anticipate this critical supportive infrastructure will grow in the years ahead. FDA's draft guidance on platforms is mostly for established, well-characterized modalities, but it also has implications for the emerging area of personalized medicine.
-
Aug 6, 2024 | 
outsourcedpharma.com | Louis Garguilo |Antony Hitchcock |AGH Bioconsulting |Alex Klarer
Not really into choosing extended time away and exhibit halls over the simple pleasures of summertime? No reason to put your CDMO search on hold – Outsourced Pharma Capacity Update’s PARTNER WEEK is now available on-demand. Take the travel and headache out of your plans and tune in right from your computer. Assess potential fit for your next drug development project in convenient 20-minute segments – all grouped by molecule type.
-
Jul 31, 2024 | 
advancingrna.com | Kimberly Benton |Antony Hitchcock |AGH Bioconsulting |Louis Garguilo
There’s been great progress in establishing platforms for linear mRNA vaccines — but where does this current know-how fall short for those exploring linear and next-gen RNA constructs for non-vaccine products? Secure your spot for Advancing RNA Live’s next digital panel discussion on the current known unknowns (and unknown unknowns) about our mRNA therapeutics candidates that make adopting the traditional QbD approach complicated. Registration is free thanks to the support of Roche Custom Biotech.
